Nervgen Pharma cash flow statement data for the quarter ended Jun 2026. This cash flow statement covers 6 quarters of results from Dec 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Dec2024 | Mar2025 | Jun2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | -2.75M | -6.57M | -1.22M | -21.12M | ||
| Share-based Compensation | 1.02M | 1.46M | 0.69M | 1.98M | ||
| Cash from Discontinued Operations | -2.87M | -5.98M | ||||
| Gains from Investment Securities | -1.39M | 1.95M | -4.17M | 13.99M | ||
| Depreciation, Depletion & Amortization | ||||||
| Amortizatization of Intangibles | 0.01M | 0.01M | 0.01M | 0.01M | ||
| Change in Working Capital | ||||||
| Change in Receivables | 0.06M | 0.17M | -0.01M | -0.08M | ||
| Change in Accured Expenses | -0.32M | 0.51M | 0.91M | -1.16M | ||
| Other Working Capital Changes | 0.51M | -0.11M | -2.24M | 0.65M | ||
| Investing Activities | ||||||
| Divestments | 0.02M | 0.02M | 0.01M | |||
| Financing Activities | ||||||
| Change in Capital Stock | ||||||
| Net Equity Issued and Repurchased | 1.14M | 0.82M | 0.00M | 59.91M | ||
| Misc. | ||||||
| Cash from Financing Activities | 0.89M | 3.43M | 2.03M | 56.49M | ||
| Exchange Rate Effect | 0.02M | 0.07M | -0.07M | -1.58M | ||
| Change in Cash | -1.95M | 0.87M | -4.02M | 50.77M | ||
| Beginning Cash Balance | 8.35M | 12.03M | 12.46M | 12.38M | 16.09M | 15.95M |
| Net Cash Flow | 0.89M | 3.43M | 2.03M | 56.49M |